19.8% BMI Reduction by Competitor Threatens Soleno’s Vykat XR Market Share
Analysts highlight that Soleno’s extended-release Vykat XR reduces hunger in Phase 2 but note Rhythm’s setmelanotide achieved a 19.8% placebo-adjusted BMI drop in 120 patients, boosting Imcivree’s market case. They project Imcivree could capture 20% of the U.S. rare obesity market, with peak sales of $1.3 billion by 2034.
1. Phase 3 Data Strengthen Imcivree’s Market Position
The pivotal TRANSCEND trial enrolled 120 hypothalamic obesity patients and demonstrated a 19.8% placebo-adjusted BMI reduction with setmelanotide, driving a significant market-cap gain and prompting an Outperform rating. This clear efficacy signal underscores Imcivree’s potential as a leading rare obesity therapy.
2. Competitive Pressure on Vykat XR
Soleno’s extended-release Vykat XR showed meaningful hunger reduction in Phase 2, but the superior BMI and hunger outcomes reported for setmelanotide, along with its favorable safety profile, position Imcivree to capture an estimated 20% of the U.S. market, threatening Vykat XR’s growth prospects.
3. Market Expansion and Sales Projections
With approximately 10,000–12,000 current Imcivree-eligible patients and an additional ~27,000 hypothalamic obesity cases globally, analysts foresee Imcivree revenues exceeding $2 billion by 2030 and peaking at $1.3 billion by 2034, especially if prescribers adopt it alongside GLP-1 therapies.